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Abstract
Introduction: The objective of the study was to assess the influence of metformin on the prevalence of cancer and risk factors for the 
development of cancer, in patients with type 2 diabetes.
Materials and methods: A total of 1063 patients, treated between October 2012 and March 2013 in the Diabetes and Endocrinology Cen-
tre in Bydgoszcz, were enrolled in the study. Only patients who were first diagnosed with diabetes and consecutively with cancer were 
included in the analysis. The final dataset compromised data from 1028 patients with type 2 diabetes, in whom retrospective analysis of 
the association between the occurrence of cancer and treatment with or without metformin was performed. Demographic data, medical 
history, physical assessment, diabetes history, diabetes complications, concomitant medication, and additional examination results were 
compared between two groups: those with cancer and those without cancer. Data were analysed using Student’s t-test, Chi-square test 
with Yates’ continuity correction, and multiple logistic regression.
Results: The most commonly observed cancer was breast cancer (24 patients; 22.5%), followed by uterine cancer (15 patients; 13.6%). Of 
the 75 diabetic patients with a cancer diagnosis, 18.7% were treated with metformin; of the 953 patients without cancer, 38% received 
metformin. Analysis of probability of cancer occurrence using Kaplan-Meier curves showed that the probability of cancer development 
was higher in groups of patients who were not treated with metformin (p = 0.006). 
Conclusions: Metformin treatment reduces the risk of cancer in type 2 diabetes patients. (Endokrynol Pol 2017; 68 (6): 652–658)
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Streszczenie
Wstęp: Metformina jest zalecana w profilaktyce raka u pacjentów z cukrzycą typu 2 (t2). Celem badania była ocena wpływu metforminy 
na częstość występowania raka i czynników ryzyka wystąpienia raka u pacjentów z cukrzycą typu 2. 
Materiał i metody: W badaniu wzięło udział 1063 pacjentów leczonych od października 2012 do marca 2013 w Bydgoskim Centrum 
Diabetologii i Endokrynologii. Do analizy włączono pacjentów, u których najpierw rozpoznano cukrzycę, a następnie raka. Ostatec-
znie uzyskano dane od 1028 pacjentów z cukrzycą t2, na podstawie których przeprowadzono retrospektywną analizę związku między 
wystąpieniem nowotworu a stosowaniem metforminy. Grupy pacjentów z rakiem i bez raka porównano pod względem danych de-
mograficznych, historii medycznej, wyników badania przedmiotowego, historii i powikłań cukrzycy, leków przyjmowanych z powodu 
chorób towarzyszących oraz wyników badań dodatkowych. Analizę statystyczną przeprowadzono za pomocą testu t Studenta, testu chi 
kwadrat z poprawką Yatesa na nieciągłość i wielokrotnej regresji logistycznej.
Wyniki: Najczęściej obserwowanym rodzajem raka był rak sutka (N = 24; 22,5%), a następnie rak macicy (N = 15; 13,6%). Spośród 75 
pacjentów chorujących na cukrzycę i nowotwór, 18,7% było leczonych metforminą, natomiast spośród 953 pacjentów bez nowotworu, 
metforminę przyjmowało 38%. Analiza prawdopodobieństwa wystąpienia raka za pomocą krzywych Kaplana-Meiera wykazała, że 
prawdopodobieństwo raka jest większe u pacjentów, którzy nie przyjmowali metforminy (p = 0,006).
Wnioski: Metformina zmniejsza ryzyko raka u pacjentów z cukrzycą t2. (Endokrynol Pol 2017; 68 (6): 652–658)
Słowa kluczowe: cukrzyca typu 2, metformina, rak
Introduction
Current epidemiological data suggest patients with 
diabetes have an increased risk of developing different 
types of cancer [1, 2]; in addition, there are reports of 
certain cancers developing more commonly in patients 
with type 2 diabetes [2]. Several types of cancer have 
been associated with obesity [2], as well as with type 2 
diabetes; for example, breast cancer [2, 3, 4], endometrial 
cancer [2, 5, 6], pancreatic cancer [2, 4], and colorectal 
cancer [2, 4, 7]. Insulin resistance and hyperinsulinemia 
may promote carcinogenesis either directly through the 
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insulin receptor or indirectly by increasing the levels of 
insulin-like growth factors (IGF). Understanding the 
relationship between diabetes and cancer, and their 
associated comorbidities and complications, may have 
important implications for the prevention and manage-
ment of these disorders [1, 8, 9].
There are many means by which type 2 diabetes is 
currently treated. A drug commonly used as an initial and 
combined therapy is metformin [2], which reduces levels 
of circulating glucose and insulin in patients who suffer 
from hyperinsulinaemia caused by insulin resistance [2]. 
The primary mode of action of metformin is through 
reduced hepatic glucose output [2, 10]. Madiraju et al. 
showed that the mechanism of action included the fol-
lowing: delayed intestinal glucose absorption, enhanced 
release of glucagon-like peptide 1, augmented lactate pro-
duction by enterocytes, and activation of AMP-activated 
protein kinase in hepatocytes as a result of decreased 
energy charge, as well as inhibition of glucagon signal-
ling, glycolytic enzymes, transcription of gluconeogenic 
enzymes, or mitochondrial complex I [11, 12].
Medications used for the treatment of hyperglycae-
mia may either increase or reduce the risk of developing 
cancer [2]. Metformin is widely used in patients with 
type 2 diabetes and has been shown to reduce the risk 
of cancer in those patients — both in small-scale studies 
[13] and in the multicentre randomised controlled UK 
Prospective Diabetes Study [14]. Not all agree on this 
association: a large, retrospective, population-based 
study using information from the healthcare databases 
in Ontario, Canada, failed to confirm the association be-
tween metformin treatment and reduced risk of prostate 
cancer in elderly men with diabetes [15]. Importantly, the 
study acknowledges the differences in study population 
characteristics to other work [15], and states that the 
populations in which the metformin effect on cancer risk 
was not observed were older, comorbid, and had worse 
grade distribution than most prostate cancer cohorts 
(contemporary cancer cohorts) [15]. It is possible that in 
a younger cohort metformin used for the treatment of type 
2 diabetes may have a positive effect on cancer risk [15]. 
The aim of the study was to assess the influence of 
treatment with metformin on the prevalence of cancer 
in patients with type 2 diabetes, and to assess risk fac-
tors, by comparing clinical characteristics of patients 
with cancer and those without cancer.
Materials and methods
Study population
A total of 1063 patients treated in the Diabetes and En-
docrinology Centre in Bydgoszcz, who were involved in 
the national health program “Comprehensive Specialist 
Outpatient Care” (in Polish: Kompleksowa Ambulatoryjna 
Opieka Specjalistyczna — KAOS), were enrolled in the 
retrospective study. The program is provided by the Po-
lish national health care system to patients with chronic 
diseases, including those with type 1 diabetes, type 2 
diabetes requiring insulin, and gestational diabetes. The 
aim of this program is to standardise specialist care of pa-
tients with chronic diseases and to secure the best patient 
management. In the case of patients with diabetes, the 
program covers a wide spectrum of specialist consultants. 
Only patients who were first diagnosed with diabe-
tes and consecutively with cancer were included in the 
analysis. As such, 20 patients for whom the diagnosis of 
cancer was reported before the onset of diabetes were ex-
cluded, as were 15 patients without a date of diagnosis of 
cancer. Patients for whom multiple cancers were reported 
were included in the study only once. The final dataset 
for analysis compromised data from 1028 patients with 
type 2 diabetes, for whom the association between cancer 
occurrence and treatment (with or without metformin) 
was analysed. The patient population was divided into 
two groups: with cancer and without cancer. 
Patient data
The following data were collected:
 — Demographics and medical history: age, sex, dura-
tion of diabetes, and comorbidities (e.g. hyperten-
sion, infarct, stroke, atrial fibrillation, atherosclerosis, 
aneurysm)
 — Physical examinations: body mass index (BMI), 
systolic and diastolic blood pressure
 — Diabetes: year of diagnosis, complications (e.g. 
retinopathy, diabetic foot, atherosclerosis, polyneu-
ropathy), and antidiabetic treatment
 — Concomitant medications: Acidum acetylsalicylicum, 
beta-blockers, alpha-blockers, calcium channel 
blockers, ACE-I, ARB, thiazides, statins, fibrates
 — Additional examinations: level of glycated haemo-
globin (HbA1c), creatinine concentration, glomerular 
filtration rate, protein concentration in urine, ami-
notransferases activity, abdomen ultrasonography, 
and echocardiography.
Data about types of cancers were collected and coded 
according to the International Statistical Classification 
of Diseases and Related Health Problems 10th Revision 
(ICD-10) [16]. 
Study timeframe
All study visits took place between October 2012 and 
March 2013. 
Ethics
The study was conducted after obtaining permission 
from the Ethics Committee, in accordance with Polish 
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Law and appropriate EU regulations on non-interven-
tional studies. 
Statistics
The statistical data are reported as the number of 
patients (n), mean (SD), median (IQR), or percentage. 
Comparisons of the data between patients with and 
without cancer were performed using a Student’s 
t-test (for numeric variables) and Chi-square test with 
Yates’ continuity correction (for categorical variables). 
Multiple logistic regression was used to examine the 
relationship between treatment (with or without met-
formin) and cancer incidence, age at study visit, and 
metformin use. P-values less than or equal to 0.05 were 
considered statistically significant.
Results
Characteristics of study population
The mean age of 1028 analysed patients was 67.9 years 
(SD 8.84 years). Women constituted 51% and men 49% of 
the study population. The differences between the men 
and women in the study population are shown in Table I. 
Overall, the mean duration of diabetes was 16.8 years 
(SD 7.54 years); the average patient weight was 86.7 kg 
(SD 15.2 kg), and the mean body mass index (BMI) was 
31.7 kg/m2 (SD 5.08 kg/m2). Of all enrolled patients, 46% 
had retinopathy, 20.8% polyneuropathy, 9.5% diabetic 
foot, 7.7% nephropathy, and 2.6% carotid atherosclerosis. 
In terms of treatments, 77.8% were treated with statins, 
69.9% with beta-blockers, 66% with acetylsalicylic acid, 
42% with thiazides, 38.1% with Ca-blockers, 11% with 
fibrates, and 3% with alpha-blockers. The mean HbA1c 
in the total study population was 8.1% (SD 1.31%). The 
mean glomerular filtration rate was 68.2 mL/min.
Table I. Characteristics of the study population stratified 
by gender
Tabela I. Charakterystyka badanej grupy w podziale na płeć
Women (n = 523) Men (n = 505)
Mean SD Mean SD
Ageat srudy visit 
(years)
69 .3 8. 93 66.4 8.50
Ageat diagnosis of 
diabetes (years)
51.7 9.46 50.5 9.07
Diabetes duration 
(years)
17.6 7.52 16.0 7.44
Height (cm) 158.8 6.09 172.3 6.44
Weight (kg) 82.2 13.75 91.4 15.37
BMI (kg/m
2
) 32.6 5.13 30.8 4.87
HbAlc (%) 8.1 1.23 8.0 1.38
Table II. Types of cancer observed in the study population, 
by ICD-10 codes
Tabela II. Typy nowotworów zaobserwowane w badanej 
grupie, sklasyfikowane według ICD-10
General 
code
ICD-
10
ICD Group Cancer group Number 
of 
reported 
cancers
C00-C14 C11 Malignant 
neoplasms of lip, 
oral cavity and 
pharynx
Nasopharyngeal 
cancer
1
C15-C26 C18
C19
C20
C22
C25
Malignant 
neoplasms of 
digestive organs
Ca colon
Ca sigmae
Ca recti
Liver cancer
Ca pancreas
11
4
7
1
1
C30-C39 C32
C34
Malignant 
neoplasms of 
respiratory and 
intrathoracic organs
Larynx cancer
Lung cancer
Ca bronchi
2
6
1
C44 C44 Other malignant 
neoplasms of skin
Ca skin
Basalioma
3
3
C45-C49 C49 Malignant 
neoplasms of 
mesothelial and soft 
tissue
Retroperitoneal
Liposarcoma
1
C50 C50 Malignant 
neoplasms of breast 
tissue
Breast cancer
Breast tumor
23
1
C51-C58 C53
C54
C55
C56
Malignant 
neoplasms of female 
genitalia
Ca of cervix uteri
Ca of corpus 
uteri
Ca uteri, part 
unspecified
Caovary
1
7
 
7
 
2
C60-C63 C60
C61
C62
Malignant 
neoplasms of male 
genitalia
Penis cancer
Ca prostate
Ca testis
1
10
1
C64-C68 C64
C67
Malignant 
neoplasms of the 
urinary tract
Ca kidney ca 
bladder
5
5
C71 C71 Malignant neoplasms 
of the brain
Brain cancer 1
C73-C75 C73 Malignant 
neoplasms of 
thyroid and other 
endocrine glands
Ca thyroid 1
C81-C96 C81
C86
C91
Malignant 
neoplasms, stated 
or presumed 
to be primary, 
of lumphoid, 
hematopoietic and 
related tissues
Hodgkin 
lymphoma
Lymphoma
Leukemia
1
 
1
6
D46 Myelodysplastic 
syndrome
1
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Cancer population
Of the total patient population, ~10% (110 patients) 
were reported to have cancer, with 115 cases of cancer 
reported. In one patient three cancer occurrences were 
reported, and in three patients two cancer occurrences 
were reported. The most commonly observed cancer 
was breast cancer (24 patients; 22.5%), followed by ute-
rine cancer (15 patients; 13.6%). Eleven patients (10%) 
were diagnosed with colon cancer, and another 10% 
with prostate cancer. The cancer types observed in our 
study population are summarised in Table II. 
Comparison of patients with and without cancer
The time from onset of diabetes to the diagnosis of 
cancer in patients treated with metformin (n = 14) 
was 9.6 years (SD 5.67 years); the time from onset of 
diabetes to the first study visit in patients without cancer 
treated with metformin (n = 362) was 15.6 years (SD 
6.55 years). The corresponding data for patients who 
did not receive metformin was 13.7 years (SD 6.99 years) 
for patients who developed cancer (n = 61), and 17.3 
years (SD 8.02 years) for patients who did not develop 
cancer (n = 591). Differences between patients with and 
without cancer were found when comparing diabetes 
duration and age at last follow-up (p < 0.05). When 
comparing the groups in terms of age at diabetes onset, 
diastolic and systolic blood pressure, BMI, or HbA1c, 
no differences were observed (Table III). When com-
paring complications of diabetes, no differences were 
observed (Table IV).
Analysis of metformin treatment and risk of 
cancer
Of the 75 diabetic patients with a cancer diagnosis, 
18.7% were treated with metformin; whereas, 38% of 
the 953 patients without cancer received metformin. 
An analysis of metformin treatment and cancer deve-
lopment is shown in Table V. Additionally, the nega-
tive association between age at study visit and use of 
metformin was identified (estimate: –0.043; p < 0.0001).
Risk of cancer
Using only patients with complete follow-up informa-
tion and a positive follow-up time, multiple logistic 
Table III. Comparison of clinical data of patients with and 
without cancer
Tabela III. Porównanie danych klinicznych pacjentów 
z nowotworem i bez nowotworu
Patients with 
cancer
Patients 
without
(n = 75) cancer  
(n = 953)
Mean (SD) Mean (SD) p
Females (%) 56 51 0.422
Metformin (%) 19 38 0.001
Age at study visit 
(years)
71.1 (7.47) 67.7 (8.89) 0.001
Age at diabetes 
diagnosis (years)
51.9 (8.89) 51.0 (9.33) 0.433
Age at cancer  
(years)
64.8 (7. 78)
Diabetes duration 
(years)
19.3 (7.23) 16.6 (7.54) 0.003
Time from diagnosis 
of cancer (years )
12.9 (6.92)
Diastolic blood 
pressure (mmHg)
77.4 (13.05) 79.0 (11.26) 0.183
Systolic blood 
pressure  
(mmHg)
149.1 (21.3) 146.9 (18. 77) 0.329
Body Mass Index 
(kg/m2)
31.7 (5.05) 31.7 (5. 08) 0.747
HbAlc (%) 7.9 (1.31) 8.1 (1.31) 0.597
Table IV. Comparison of diabetes complications in patients 
with and without cancer
Tabela IV. Porównanie powikłań cukrzycy z nowotworem 
i bez nowotworu
Patients  
with cancer
Patients  
without cancer
(n = 75) (n = 953)
N % % p
Complications 0.869
No 27 36 359 37.7
Yes 48 64 594 62.3
Retinopathy 0.651
No 38 50.7 515 54
Yes 37 49.3 438 46
Diabetic foot 0.797
No 69 92 861 90.3
Yes 9 8 92 9.7
Carotid atherosclerosis
No 74 98.7 927 97.3
Yes 1 1.3 26 2.7
Polyneuropathy 0.357
No 63 84 751 78.8
Yes 12 16 202 21.2
Microalbuminuria  
> 30 mg/day
0.569
No 71 94.7 878 92.1
Yes 4 5.7 75 7.9
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regression showed metformin treatment had a signifi-
cant positive effect on cancer incidence (p = 0.006). In 
addition, this analysis indicated that the longer the 
duration of diabetes, the greater the risk of cancer (p = 
0.032) and that the use of acetylsalicylic acid (p = 0.002) 
(Table VI). The age of diabetes onset, gender, and BMI 
did not prove to be predictors of cancer, nor did HbA1c 
level, acetylsalicylic acid dose, non-proliferative retin-
opathy, proliferative retinopathy, diabetic foot, carotid 
atherosclerosis, polyneuropathy and nephropathy, 
or anticoagulant therapy (Table VI). Analysis using 
Kaplan-Meier curves showed that the probability of 
developing cancer was higher in patients who were 
not treated with metformin, compared to those who 
were (p = 0.006; Fig. 1).
Discussion
In the current study, we observed metformin to 
have a protective effect in patients with type 2 dia-
betes, specifically by preventing the development 
of cancer. The study was performed in patients who 
were under strict professional control because they 
belonged to the Comprehensive Outpatient Specia-
list Care program. Our findings are supported by 
a comparison of metformin-treated and untreated 
patients, as well as by multiple logistic regression. 
Our Kaplan-Meier curves also showed that the risk 
of developing cancer was higher in patients who 
were not treated with metformin. This observation 
is in line with the currently understood mechanism 
of action of metformin. 
Table VI. Multiple logistic regression of patients with 
complete information
Tabela VI. Wielokrotna regresja logistyczna u pacjentów 
z kompletnymi danymi
Estimate Standard 
error
Z value P value
(Intercept) –4.082 1.667 –2.448 0.014
Diabetes duration 0.044 0.021 2.099 0.036
Age at diabetes onset 0.021 0.017 1.218 0.223
BMI 0.031 0.029 1.086 0.277
Gender (woman) 0.047 0.276 0.169 0.865
Metformin –0.940 0.341 –2.758 0.006
Complications –0.064 0.285 –0.226 0.821
HbAIC –0.038 0.108 –0.352 0.725
Beta blocker 0.225 0.308 0.730 0.466
Thiazides diuretics –0.296 0.298 –0.994 0.320
Loop diuretics 0.254 0.372 0.683 0.494
Potassium-sparing 
diuretics
–0.806 0.631 –1.277 0.202
Acetylsalicylic acid –0.859 0.277 –3.104 0.002
Stalin –0.234 0.314 –0.748 0.455
Fibrate –0.735 0.618 –1.189 0.235
Alfa blocker –15.374 730.262 –0.021 0.983
Ca blocker 0.101 0.286 –0.353 0.724
Anticoagulants 0.260 0.433 0.602 0.547
Table V. Comparison of patients with and without cancer, 
stratified by treatment
Tabela V. Porównanie pacjentów z nowotworem i bez 
nowotworu w zależności od rodzaju terapii
Metformin Cancer N Mean SD p
No
Age at 
study visit 
(years)
No
Yes
591
61
68.81
72.02
9.401
7.152 0.002
Age at 
diabetes 
diagnosis 
(years)
No
Yes
591
61
51.52
52.23
9.726
8.543 0.590
Diabetes 
duration 
(years)
No
Yes
591
61
17.28
19.79
8.021
7.492 0.020
Yes
Age at last 
follow-up 
(years)
No
Yes
362
14
65.79
67.21
7.644
7.837 0.500
Age at 
diabetes 
diagnosis 
(years)
No
Yes
362
14
50.19
50.29
8.589
10/499 0.970
Diabetes 
duration 
(years)
No
Yes
362
14
15.60
16.93
6.553
5.609 0.460
Figure 1. Analysis of the probability of cancer development using 
Kaplan-Meier curves. Log Rank (Mantel-Cox) (p = 0.006)
Rycina 1. Prawdopodobieństwo wystąpienia nowotworu 
przedstawione za pomocą krzywej Kaplana-Meiera. Log Rank 
(Mantel-Cox) (p = 0,006)
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Metformin is likely to inhibit cell proliferation and 
reduce colony formation, as shown in in vitro studies 
of cancer cell lines [2, 17–19]. It induces muscles to take 
up glucose from the blood through targeting of the 
AMP-activated protein kinase (AMPK). The mechanism 
is also known to be dependent on the activation of the 
protein kinase LKB1 — a tumour suppressor [13]. It is 
probable that this correlation is beneficial in the primary 
and secondary prevention of certain types of cancers [13]. 
It is most probable that the influence of metformin on 
LKB1 or AMPK is secondary to its effect on mitochon-
dria, which are the primary target of the drug [20]. 
The intensive glucose control observed following 
metformin treatment appeared to reduce the risk of 
diabetes-related health complications (including death) 
when compared to insulin and sulfonylureas [20]. 
Metformin may show a prevention role of cancer [21]. 
Metformin-induced activation of AMPK in tumour 
cells is suggested to lead to inhibition of cell growth, 
at least in part by inhibiting protein synthesis [2]. An-
other mode of action of metformin might be through 
an AMPK-mediated regulation of fatty acid synthesis. 
Prostate, breast, and colon cancers cells constitutively 
over-express fatty acid synthase, which is a key enzyme 
for de novo fatty acid biosynthesis, and has been associ-
ated with the malignant phenotype. Another potential 
mechanism is based on the positive impact of met-
formin on chronic inflammation. Metformin not only 
inhibits the proliferation of cancer cells, it also promotes 
cell death of these same cells by activating apoptotic 
pathways. It has also been suggested that metformin 
can inhibit the growth of cancer cells by decreasing their 
energy status and forcing a metabolic conversion that 
cancer cells are unable to execute [21].
Results of other observational human studies also 
indicate that therapy with metformin is associated 
with reduced risk of cancer [2, 13, 22–24] and cancer 
morta lity [2, 25]. Observational data suggest metformin 
might improve cancer prognosis as well [2]. 
Type 2 diabetes is associated with increased risk 
of cancer affecting the breast, colon, prostate, kidney, 
and pancreas [2, 21]. The most common type of cancer 
observed in patients in our study population was breast 
cancer, which is similar to the observations of Giova-
nucci et al. [2], Michels et al. [3], and Coughlin et al. [4]. 
Other common cancers included uterine cancer, colon 
cancer, and prostate cancer. A number of studies have 
discussed the mechanisms underlying the relationship 
between diabetes and cancer; however, a metabolic or 
biochemical reliance is thought to be key. The associa-
tion between the two diseases appears to be mediated 
through the metabolic system [1]. Both diseases, which 
are likely to be biologically linked through an as-yet- 
-unknown mechanism, share the range of potential risk 
factors: both modifiable and non-modifiable [2]. Non- 
-modifiable risk factors are: age, gender, and ethnicity; 
whereas, modifiable risk factors are: weight, obesity, 
weight change, diet, physical activity, smoking status, 
and alcohol consumption [2]. In the current study, we 
did not observe any relationship between BMI and risk 
of cancer development. It has been observed that both 
the occurrence of cancer and diabetes increase with age 
and gender: men have a slightly higher age-adjusted 
risk of diabetes than women [2]. In the current study, 
gender did not influence the risk of cancer develop-
ment. 
The incidence of tumours in the current study was 
almost twice that recently reported for the general Pol-
ish population of patients with type 2 diabetes (5.9%) 
[26]. This result can be explained by the nature of the 
patients included in the Comprehensive Outpatient 
Specialist Care program when compared with the 
general population; specifically, patients included in 
this program are at a more advanced disease stage but, 
at the same time, they are subjected to more thorough 
care with better screening of other comorbid diseases. 
In addition, the observed incidence of the individual 
tumours is a little different, and may be explained by 
differences between study populations (for example, 
diabetes duration). Like the authors of other studies, 
we did not observe a correlation between the incidence 
of cancer and the degree of glycaemic control (as meas-
ured by glycated haemoglobin levels), weight, or dura-
tion of diabetes. Perhaps such a relationship would be 
able to be observed for individual types of cancer, but 
the study would require a larger population. 
The results of our study should be interpreted 
with caution, in light of the retrospective nature of the 
study. We did not have the exact date of metformin 
implementation, and assumed that metformin had 
been administered very early in the course of diabetes; 
that is, that the duration of diabetes was equal to the 
duration of treatment with metformin. Moreover, we 
did not have information about other risk factors for 
cancer development, such as family history or lifestyle 
parameters. Another limitation of our study was the fact 
that our population differed from the general popula-
tion with type 2 diabetes. First of all, the patients co-
vered by the Comprehensive Outpatient Specialist Care 
program suffered from more advanced type 2 diabetes, 
and appeared to have more problems with controlling 
the disease, as indicated by an increased HbA1c value. 
The mean HbA1c in our study was slightly higher than 
in the patient population reported by Sieradzki et al. 
(mean HbA1c — 7.7%), who nevertheless postulated 
the need for earlier and more intensive treatment [27]. 
Therefore, we would like to reiterate that our findings 
are specific to the population of patients with more 
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severe and poorer controlled type 2 diabetes compared 
to the overall population. Finally, we should underline 
that the negative association between metformin use 
and age could at least partly contribute to the observed 
association between metformin use and the likelihood 
of cancer. The association between metformin use and 
age was weak, and that is why we would consider it as 
a minor confounder. All of these facts need to be taken 
into account when interpreting the results of our study.
Conclusions
To conclude, as suggested by many observational stud-
ies, therapy with metformin reduces the risk of cancer. 
In our trial, the protective effect of metformin was con-
firmed. These results are of high clinical significance bec-
uase metformin is widely used, generally well tole rated, 
and commonly accepted. Long-term observational trials 
in larger group of patients should be performed, and 
they will be crucial in directing future research. 
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